Wordt geladen...
Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice
Non-alcoholic steatohepatitis (NASH) has no approved therapy. The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. Therefore, the present study aimed to investigate the effects and underlying mecha...
Bewaard in:
| Gepubliceerd in: | Exp Ther Med |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
D.A. Spandidos
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8200799/ https://ncbi.nlm.nih.gov/pubmed/34149876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2021.10262 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|